

Emerging plasmid-encoded colistin resistance: the animal world as the culprit?

Laurent Poirel^{1*} and Patrice Nordmann^{1,2}

¹Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg, Switzerland;
²HFR - Hôpital Cantonal, Fribourg, Switzerland

*Corresponding author. E-mail: laurent.poirel@unifr.ch

Sir,

A recent study from China identified transferable polymyxin resistance in Gram-negative bacilli from human and animal isolates.¹ Although polymyxins, including colistin and polymyxin B, were among the very few antibiotics for which no transferable resistance had been identified, we are now facing a novel threat with the identification of a plasmid-encoded resistance mechanism. Colistin is an old drug that was first introduced in 1959 but remained on the shelf for many years due to renal and neurotoxicity.² However, we are experiencing a renewed interest in this drug due to the rapid emergence of MDR Gram-negative organisms.

The plasmid-borne *mcr-1* gene encodes a phosphoethanolamine transferase that mediates addition of phosphoethanolamine to the lipid A moiety of the lipopolysaccharide, consequently conferring resistance to polymyxins.¹ This gene has thus far mainly been found in *Escherichia coli*, and to a lesser extent in *Klebsiella* spp. and *Salmonella* spp.

Very shortly after the original report, other studies reported identification of the *mcr-1* gene in human *E. coli* isolates in many different countries, including in Algeria, Denmark, France, Germany, Laos, the Netherlands, Malaysia, Nigeria, Switzerland and Thailand.³⁻⁵ It was also identified from imported food products in Denmark (meat) and Switzerland (vegetables).^{6,7} In addition, plasmid-encoded carbapenem and colistin resistance may be co-associated in *E. coli*.^{3,5,8} In addition, positive *Salmonella enterica* isolates of different serotypes were identified from food samples in Portugal in 2011, and France in 2012 and 2013.^{9,10} Finally, an epidemiological survey conducted in France on a collection of ESBL-producing *E. coli* isolates ($n=517$) recovered from the faeces of diarrheic veal calves on farms from 2005 to 2014 showed a very high rate of MCR-1-positive isolates (20.5%).¹¹

Taken together, these findings indicate that: (i) the spread of *mcr-1* is not recent, as it has already occurred worldwide, probably due to its location on conjugative plasmids; and (ii) *E. coli* is so far the main reservoir of this resistance trait among human, animal and environmental isolates. This is a source of concern since *E. coli* isolates are easily exchanged from the environment to humans in which they may remain as a commensal in the gut flora; in addition, *E. coli* is the number one pathogen for humans.

MCR-1 is one of the few and clear examples of the animal origin of a resistance trait that may later hit the entire human health system, along with the examples of some MRSA clones (such as CC398), the serotype O104:H4 CTX-M-15 ESBL-producing enteroaggregative *E. coli* and ESBL-producing *Salmonella* spp. strains.

The animal origin of MCR-1 is sustained by: (i) the number of reports of animal isolates expressing *mcr-1*, which is already high; and (ii) heavy usage of colistin in veterinary medicine. By standardizing the sales of antimicrobials in relation to the total weight of animals 'at risk' undergoing treatment across Europe in 2011, it was estimated that polymyxins are the fifth most sold group of antimicrobials (7%).¹² In Europe, colistin and polymyxin B are used for treating infections caused by Enterobacteriaceae in rabbits, broilers, veal, beef cattle, dairy cattle and (primarily) pigs. In addition, in other parts of the world, polymyxins are used as growth promoters, a usage that has been banned in Europe since 2006. The animal origin of MCR-1 is also sustained by the genetics associated with the *mcr-1* gene. When investigating the *mcr-1*-positive *E. coli* KRI recovered from the urine of a community patient in Switzerland,³ an insertion sequence (*ISAp1*) was identified upstream of the *mcr-1* gene that was 100% identical to one identified in *Pasteurella multocida*, which is a common animal pathogen, in particular for pigs. In addition, this same *E. coli* co-expressed the broad-spectrum β -lactamase gene *bla*_{CMY-2}, and the florfenicol resistance gene *floR*, both genes that are widely disseminated in animal isolates, with florfenicol being used in veterinary medicine only.

It seems very likely that the occurrence of polymyxin resistance in animal isolates has been underestimated and unrecognized for years, since the determination of polymyxin susceptibility is difficult. Disc diffusion and Etest are not reliable techniques, and broth microdilution is the gold standard technique but it is cumbersome and not used on a regular basis, in particular in veterinary medicine. Therefore, there is an urgent need for rapid diagnostic tests for polymyxin resistance in Enterobacteriaceae.

The impact of the use of polymyxins in agriculture was not seriously taken into account as long as there was no critical need for colistin in human medicine. However, times have changed and a co-ordinated re-evaluation of polymyxin usage in agriculture is urgently needed to prevent selection in veterinary medicine of polymyxin-resistant isolates that might subsequently be transferred to humans. Similarly, using polymyxins in selective digestive decontamination to prevent the spread of MDR bacteria in hospitals should be discouraged. Nevertheless, a decision to ban polymyxins in agriculture would be far from simple and might be a matter of balancing risk against benefits.

In a recent review debating the use of colistin-containing products within the European Union and European Economic Area, Catry *et al.*¹² concluded by stating 'Should colistin resistance determinants be found on mobile genetic elements in bacteria of concern from human or animal origin, or should a clonal expansion of pathogenic polymyxin-resistant bacteria take place, further risk profiling would be required'. Here we are, unfortunately!

Funding

This work was funded by the University of Fribourg, Switzerland.

Transparency declarations

None to declare.

References

- 1 Liu YY, Wang Y, Walsh TR *et al.* Emergence of plasmid-mediated colistin-resistance mechanism MCR-1 in animals and human beings in China: a microbiological study and molecular biology study. *Lancet Infect Dis* 2016; **16**: 161–8.
- 2 Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to polymyxins: Mechanisms, frequency and treatment options. *Drug Resist Updat* 2010; **13**: 132–8.
- 3 Poirel L, Kieffer N, Liassine N *et al.* Plasmid-encoded carbapenem and colistin resistance in a clinical isolate of *Escherichia coli*. *Lancet Infect Dis* 2016; **16**: 281.
- 4 Olaitan AO, Chabou S, Okdah L *et al.* Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 2016; **16**: 147.
- 5 Falgenhauer L, Waezsada SE, Yao Y *et al.* Colistin resistance gene *mcr-1* in extended-spectrum β -lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. *Lancet Infect Dis* 2016; **16**: 282–3.
- 6 Hasman H, Hammerum AM, Hansen F *et al.* Detection of *mcr-1* encoding plasmid-mediated colistin-resistant *Escherichia coli* isolates from human bloodstream infection and imported chicken meat, Denmark 2015. *Euro Surveill* 2015; **20**: doi:10.2807/1560-7917.ES.2015.20.49.30085.
- 7 Zurfluh K, Poirel L, Nordmann P *et al.* Occurrence of the plasmid-borne *mcr-1* colistin resistance gene in ESBL-producing Enterobacteriaceae in river water and imported vegetable samples in Switzerland. *Antimicrob Agents Chemother* 2016; in press.
- 8 Yao X, Doi Y, Zeng L *et al.* Carbapenem-resistant and colistin-resistant *Escherichia coli* co-producing NDM-9 and MCR-1. *Lancet Infect Dis* 2016; in press.
- 9 Figueiredo R, Henriques A, Sereno R *et al.* Antimicrobial resistance and extended-spectrum β -lactamases of *Salmonella enterica* serotypes isolated from livestock and processed food in Portugal: an update. *Foodborne Pathog Dis* 2015; **12**: 110–7.
- 10 Webb HE, Granier SA, Marault M *et al.* Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 2016; **16**: 144–5.
- 11 Haenni M, Poirel L, Kieffer N *et al.* Co-occurrence of extended-spectrum and β -lactamase and MCR-1 encoding genes on plasmids. *Lancet Infect Dis* 2016; **16**: 281–2.
- 12 Catry B, Cavaleri M, Baptiste K *et al.* Use of colistin-containing products within the European Union and European Economic Area (EU/EEA): development of resistance in animals and possible impact on human and animal health. *Int J Antimicrob Agents* 2015; **46**: 297–306.